UNSPSC 51362303: Metoserpate

This classification denotes a sedative and hypnotic with the molecular formula C24H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X3G4L02XQU, chemically known as 3.beta., 20.alpha.-yohimban-16.beta.-carboxylic acid, 11,17.alpha., 18.alpha.-trimethoxy-, methyl ester, monohydrochloride but generally known as metoserpate, which bears US NIH Compound Identifier 14443. European Medicines Agency schedules Metoserpate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08911MIG.

UNSPSC 51362303 Metoserpate, a Commodity code, appears in state and local procurement activity centered on pharmaceutical and health product supply. Recent solicitations show demand for naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple state and local jurisdictions across participating regions). The scope of work spans product procurement with specific compliance requirements—FDA approval, current Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and electronic data interchange capability for wholesaler integration—as well as strategic program design for pharmacy benefit administration. Vendors must meet insurance, workplace compliance, and product shelf-life standards, with contracts typically structured as fixed-fee arrangements or competitively priced frameworks with administrative fees.

Geographic activity centers on Florida, Texas, and Minnesota, with the cooperative purchasing vehicle extending reach to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026; response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to Sanford; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs to improve fulfillment efficiency; and MMCAP's RFP S1070000015802 (posted January 20, 2026; response due March 26, 2026) establishing multi-awards for generic pharmaceuticals and OTC products across authorized wholesalers, with contract performance effective July 1, 2026, and evaluations weighted 75 percent on price competitiveness. The Seminole County procurement requires drug-free workplace certification and E-Verify compliance; the MMCAP solicitation imposes performance penalties of $200 to $1,500 per violation and requires $5,000,000 commercial general liability coverage.